3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Dermatologic
1
Conditions
Vomiting
6
Nausea
3
Neoplasms
2
Uterine Neoplasms
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Ovarian Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Multiple Myeloma
1
Melanoma
1
Gynecologic Cancer
1
Gastrointestinal Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Ipilimumab
98
pembrolizumab
84
Nivolumab
82
aldesleukin
51
Cyclophosphamide
49
Interleukin-2
38
fludarabine phosphate
31
Vemurafenib
31
Dacarbazine
31
dabrafenib
29
trametinib
28
Temozolomide
26
fludarabine
25
CTLA-4 Antigen
18
Bevacizumab
18
Radiosurgery
15
Paclitaxel
15
Carboplatin
14
encorafenib
13
binimetinib
13
Introns
13
talimogene laherparepvec
12
Radiotherapy
12
Interferon alpha-2
12
spartalizumab
11
cobimetinib
10
atezolizumab
10
sargramostim
9
peginterferon alfa-2b
9
montanide ISA 51
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Melanoma
×
fosaprepitant
×
Clear all
NCT01874119
2018-06-07
HDIL2/Emend
St. Louis University
Phase 2
Terminated
13 enrolled
7 charts